NVCoV-2 is under clinical development by NanoViricides and currently in Phase I for Respiratory Syncytial Virus (RSV) Infections. According to GlobalData, Phase I drugs for Respiratory Syncytial Virus (RSV) Infections have a 69% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how NVCoV-2’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

NVCoV-2 overview

NV-CoV-2 is under development for the treatment of coronavirus disease 2019 caused due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), middle east respiratory syndrome (MERS), bird flu H5N1,Influenza A H3N2   SARS-CoV-1 and respiratory syncytial virus (RSV) infections, monkeypox, alaskapox and smallpox infections. The drug candidate is administered through oral route in the form of syrup and gummies (chewable gel), parenteral route in the form of solution and inhalational route. It is a polymeric drug candidate, being developed based on nanoviricide platform.

The drug candidate was under development for the treatment of long Covid.

NanoViricides overview

NanoViricides is a nano-biopharmaceutical company that discovers, develops, and commercializes therapeutics to treat patients suffering from life-threatening viral infections. The company offers nanoviricide drug candidates against epidemic influenzas and bird flu, HIV/AIDS, cold sores and genital herpes infection, viral eye diseases, and dengue viruses. NanoViricides provides skin cream for the treatment of shingles caused by aka varicella-zoster virus; skin cream for the treatment of orolabial herpes and recurrent herpes labialis (RHL) caused by herpes simplex virus type 1; ocular eye drops treatment for external eye herpes keratitis (HK), caused by HSV-1 or herpes simplex virus type 2 (HSV-2), skin cream for the treatment of genital herpes caused by HSV2, and others. It conducts research in the areas of medical science and pharmaceutical technology. NanoViricides is headquartered in Shelton, Connecticut, the US.

For a complete picture of NVCoV-2’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.